BRCA1、RRM1和TUBB3基因在非小细胞肺癌中的表达及其与化疗的关系 |
| |
引用本文: | 阳诺,;马辉,;冼磊,;陈铭伍.BRCA1、RRM1和TUBB3基因在非小细胞肺癌中的表达及其与化疗的关系[J].微创医学,2014(4):389-393. |
| |
作者姓名: | 阳诺 ;马辉 ;冼磊 ;陈铭伍 |
| |
作者单位: | [1]广西医科大学第一附属医院心胸外科,南宁市530021; [2]广西医科大学第一附属医院结直肠肛门外科,南宁市530021 |
| |
基金项目: | 广西科学研究与技术开发计划项目(合同号:桂科攻10124001A-44);广西区卫生厅科研项目(合同号:Z2011329) |
| |
摘 要: | 肺癌已成为世界上发病率和死亡率最高的恶性肿瘤之一,根治性手术切除及术后辅助化疗是其主要的治疗方法。然而,由于肿瘤细胞的耐药性,对于非小细胞肺癌(non-small cell lung cancer,NSCLC)患者术后辅助化疗的效果却不尽如人意。近年来,研究表明有效预测NSCLC患者化疗敏感性和耐药性的靶向分子和指标有助于提高NSCLC个性化化疗效果。本文就BRCA1、RRM1和TUBB3基因作为预测NSCLC化疗疗效的重要参考指标的研究现状作一综述。
|
关 键 词: | 肺癌 BRCA1 RRM1 TUBB3 化疗 |
The expression of BRCA1, RRM1 and TUBB3 and their relationship with chemotherapy in patients with non-small cell cancer |
| |
Institution: | YANG Nuo ,MA Hui ,XIAN Lei , CHEN Minwu (1 Department of Cardiothoracic Surgery; 2 Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021 ,P. R. China) |
| |
Abstract: | Lung cancer (NSCLC) has become one of the most common and fatal malignant tumors worldwide. Radical operation and postoperative adjuvant chemotherapy are its main treatment methods. However, because of the drug resistance of tumor cell, the effect of postoperative adjuvant chemotherapy is not satisfactory for non-small cell cancer (NSCLC) . Recently, studies demonstrates that effective predictive markers of chemo-sensitivity and drug resistance will be beneficial to the individual treatment of NSCLC patients. This article will review the evidences regarding breast cancer susceptibility gene 1 (BRCAI), ribonucleotide reductase subunit 1 ( RRM1 ), and β-tubulin Class Ⅲ ( TUBB3 ) as new predictive markers for chemotherapy of NSCLC. |
| |
Keywords: | Lung Cancer Breast cancer susceptibility gene 1 Ribonucleotide reductase subunit 1 β-tubulin Class Ⅲ Chemotherapy |
本文献已被 CNKI 维普 等数据库收录! |
|